MKT Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$547K Sell
2,008
-158
-7% -$40.5K 0.18% 66
2026
Q2
$552K Sell
2,166
-545
-20% -$117K 0.17% 75
2026
Q1
$559K Sell
2,711
-8
-0.3% -$1.78K 0.19% 72
2025
Q4
$599K Buy
2,719
+1
+0% +$228 0.2% 70
2025
Q3
$664K Sell
2,718
-148
-5% -$30.1K 0.25% 62
2025
Q2
$544K Sell
2,866
-14
-0.5% -$2.6K 0.22% 69
2025
Q1
$537K Sell
2,880
-75
-3% -$14.6K 0.25% 58
2024
Q4
$507K Sell
2,955
-84
-3% -$15.4K 0.22% 68
2024
Q3
$598K Sell
3,039
-193
-6% -$36K 0.28% 58
2024
Q2
$543K Sell
3,232
-46
-1% -$7.62K 0.27% 65
2024
Q1
$554K Sell
3,278
-14
-0.4% -$2.41K 0.3% 61
2023
Q4
$534K Sell
3,292
-220
-6% -$32.1K 0.35% 58
2023
Q3
$521K Sell
3,512
-28
-0.8% -$4.11K 0.39% 55
2023
Q2
$534K Sell
3,540
-213
-6% -$31.2K 0.38% 55
2023
Q1
$603K Buy
3,753
+13
+0.3% +$1.99K 0.45% 50
2022
Q4
$588K Sell
3,740
-134
-3% -$20.5K 0.44% 54
2022
Q3
$520K Sell
3,874
-34
-0.9% -$4.88K 0.45% 53
2022
Q2
$599K Buy
3,908
+2
+0.1% +$306 0.47% 47
2022
Q1
$590K Buy
3,906
+138
+4% +$20K 0.45% 49
2021
Q4
$506K Buy
+3,768
New +$445K 0.4% 53

Other funds holding ABBV

MKT Advisors's ABBV Position: Q3 2026 in Review

MKT Advisors reduced its AbbVie (ABBV) stake by 7.3% in Q3 2026, selling an estimated $40.5K and leaving 2,008 shares worth $547K. The position accounts for 0.18% of the portfolio, ranked #66.

MKT Advisors first reported a position in ABBV in Q4 2021 and has held it in 20 quarters since. The position peaked at $664K in Q3 2025. 1,336 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • MKT Advisors held 2,008 shares of AbbVie worth $547K as of Q3 2026.
  • MKT Advisors sold 158 AbbVie shares in Q3 2026, an estimated $40.5K.
  • AbbVie made up 0.18% of MKT Advisors's portfolio in Q3 2026, its #66 holding.
  • MKT Advisors first reported a position in AbbVie in Q4 2021 and has held it in 20 quarters since.
  • MKT Advisors's AbbVie position peaked at $664K in Q3 2025.
  • 1,336 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on MKT Advisors's 13F filing for Q3 2026, filed 20 Oct 2026.